Biocartis announces that its researchers, in collaboration with researchers at the Wellcome Trust Sanger Institute and at Philips Research, are developing a novel workflow for extraction and amplification & detection of tumor DNA on Biocartis diagnostic platforms. Biocartis retains its full ... more
Illumina and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil
Uncovering Mutations Found in Deadly Transmissible Cancer Could Help Conservation Efforts
Researchers from Illumina, Inc. and the Wellcome Trust Sanger Institute have used Illumina's next generation sequencing technology to create a draft genome sequence for the endangered Tasmanian devil, and will use this to find genetic mutations in the transmissible cancer that is ravaging its population.
The results open the door for new research to pick out those specific mutations that drive the cancer and will lay the foundation for ongoing work to trace the spread of disease and inform the development of preclinical tests, conservation strategies and disease therapies. The announcement is being made by Sanger Institute researcher, Dr. Elizabeth Murchison, at the AMATA 2010 Conference in Hobart, Tasmania, Australia.
The reference Tasmanian devil genome - approximately the same size as the human genome - was sequenced in eight days in one run on Illumina's HiSeq 2000, generating more than 80-fold genome coverage. Two cancer genomes of affected animals from different parts of Tasmania were sequenced at high coverage as well. Sequencing, de novo assembly and analysis of genetic variation of the three genomes has been undertaken jointly by scientists at the Wellcome Trust Sanger Institute and Illumina.
"We're excited about what this project means, not just for the future of this very rare and endangered species and this unusual cancer," said David Bentley, Chief Scientist at Illumina. "It is wonderful to see Illumina's next generation sequencing, with its emphasis on speed, accuracy and genome coverage, opening a world of new possibilities for scientists to get at the root causes and manifestations of disease."
Tasmanian devil facial tumor is almost unique in cancers of the animal kingdom in that it is transmitted by direct transplantation of cancer cells from animal to animal.
"This sequence is invaluable and comes at a crucial time," said Dr. Murchison. "By comparing our draft sequence with samples taken from many hundreds of devils suffering from this cancer, we can begin to look at the spread of the disease, quite literally, by identifying geographical routes and barriers in its transmission. This knowledge could ultimately shape the ongoing conservation efforts in Tasmania.
"It took 10 years to sequence the draft human genome; the devil took just two months using this new technology. We are entering a new era when genome sequencing can be applied to some of our most pressing problems in real time."
The next step will be to sequence many more Tasmanian devil facial tumor samples. By generating profiles of the mutations present in these cancers, the team hopes to improve understanding of the disease and its spread.
Oxford Gene Technology (OGT) has successfully completed processing more than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium (WTCCC), the world’s largest CNV study involving a collaboration of 24 human geneticists. The project analysed DNA samples from ... more
Wellcome Trust Sanger Institute scientists have developed a new large-scale method to identify the interactions between proteins that are a major target for therapeutic intervention. The novel method can identify the weak, short-lived interactions that are characteristic of cell responses t ... more
Illumina, Inc. and Pacific Biosciences announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weigh ... more
Analytik Jena has entered a partnership with Illumina, Inc. headquartered in San Diego. In so doing Analytik Jena gains access to the growing genotyping market currently being served by Illumina’s technologies by offering a production scale solution to provide ultra-high throughput sample p ... more
Merck Serono and Illumina, Inc., announced a collaboration to expand the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies. Under the terms of the agreement, Merck Serono and Illlumina will work together to devel ... more
Every year hundreds of thousands of people die from diarrhoeal diseases caused by ETEC bacteria. A study published in Nature Genetics describes how Swedish researchers have mapped the spread of strains of ETEC bacteria around the world. It provides key information about how pathogenic bacte ... more
Research using data collected from around 4,000 healthy people in the UK has enabled scientists to identify a rare genetic variant that dramatically reduces levels of certain types of lipids in the blood. The study is the first to emerge from the UK10K Project's cohort of samples from the g ... more
Concealed within the vastness of the human genome, (comprised of some 3 billion base pairs), mutations are commonplace. While the majority of these appear to have neutral effect on human health, many others are associated with diseases and disease susceptibility. Reed Cartwright, a research ... more
- 1Can the AI driving ChatGPT help to detect early signs of Alzheimer's disease?
- 2Simple nasal swab can provide early warning of emerging viruses
- 3Holes in T cells
- 4Diagnosing cancer in minutes
- 5A mobile breakthrough for water environment monitoring
- 6Molecular archeology: 1200-year-old DNA sequences from Madagascar lead to the discovery of an extinct tortoise
- 7Sartorius with clear double-digit growth in fiscal 2022
- 8Bruker Announces Acquisition of ACQUIFER Imaging GmbH
- 9How old is your brain, really?
- 10The architecture of shattered genomes